Deutsche Bank Aktiengesellschaft Forecasts Strong Price Appreciation for Haleon (LON:HLN) Stock

Haleon (LON:HLN) had its price target boosted by research analysts at Deutsche Bank Aktiengesellschaft from GBX 325 to GBX 335 in a research note issued on Friday,Digital Look reports. The brokerage currently has a “sell” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential downside of 8.84% from the stock’s previous close.

A number of other equities research analysts also recently issued reports on the stock. Jefferies Financial Group reaffirmed a “buy” rating and issued a GBX 400 price objective on shares of Haleon in a research report on Friday. JPMorgan Chase & Co. dropped their target price on shares of Haleon from GBX 335 to GBX 315 and set an “underweight” rating on the stock in a research report on Thursday, June 25th. Royal Bank Of Canada reaffirmed a “sector perform” rating and issued a GBX 370 target price on shares of Haleon in a report on Thursday, April 30th. Finally, Berenberg Bank reaffirmed a “buy” rating and set a GBX 512 price target on shares of Haleon in a research report on Thursday, April 30th. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Haleon has an average rating of “Hold” and an average price target of GBX 395.33.

Haleon Price Performance

HLN opened at GBX 367.50 on Friday. The company has a debt-to-equity ratio of 52.26, a current ratio of 0.92 and a quick ratio of 0.93. The company has a market capitalization of £32.37 billion, a price-to-earnings ratio of 19.86, a P/E/G ratio of 1.49 and a beta of 0.24. The firm’s fifty day moving average price is GBX 349.45 and its two-hundred day moving average price is GBX 363.11. Haleon has a 1 year low of GBX 317.80 and a 1 year high of GBX 416.10.

Haleon (LON:HLN) last announced its earnings results on Thursday, July 30th. The company reported GBX 8.60 EPS for the quarter. Haleon had a net margin of 15.11% and a return on equity of 10.30%. As a group, analysts anticipate that Haleon will post 19.5033282 earnings per share for the current fiscal year.

Haleon Company Profile

Haleon (LSE / NYSE: HLN) is a world-leading consumer health company, with a clear purpose to deliver better everyday health with humanity. In July 2022, it listed as an independent company on the London and New York Stock Exchanges.

Haleon’s product portfolio spans six major categories – Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands – such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren – are built on trusted science, innovation and deep human understanding.